Gosalia, Helin
Moreno-Ajona, David
Goadsby, Peter J.
Funding for this research was provided by:
National Institute of Health and Social Care Research, South London and the Maudsley Biomedical Research Centre (NIHR203318)
Article History
Received: 6 February 2024
Accepted: 22 March 2024
First Online: 31 May 2024
Declarations
:
: Peter J. Goadsby reports, over the last 36 months, grants and personal fees from Eli-Lilly and Company, grant from Celgene, and personal fees from Aeon Biopharma, Allergan/Abbvie, Amgen, Biodelivery Sciences International, Biohaven Pharmaceuticals Inc., CoolTech LLC, Dr Reddys, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Novartis, Praxis, Sanofi, Satsuma and Teva Pharmaceuticals, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric, and fees for educational materials from CME Outfitters, Omnia Education, WebMD, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer, and for medicolegal advice in headache, and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee. Helin Gosalia has nothing to report. David Moreno-Ajona has nothing to report.